CMMB
ChemomabยทNASDAQ
--
--(--)
--
--(--)
CMMB Profile
Chemomab Therapeutics Ltd.
A clinical-stage biotech company focused on innovative therapeutics for fibrotic and inflammatory diseases
Biological Technology
09/22/2011
02/12/2019
NASDAQ Stock Exchange
16
12-31
Depository Receipts (Ordinary Shares)
Kiryat Atidim, Building 7, Tel Aviv 6158002, Israel
--
Chemomab Therapeutics Ltd., was incorporated in Israel on September 22, 2011 under the Israeli Companies Law. Chemomab is a clinical-stage biotechnology company dedicated to discovering and developing innovative therapies for fibrosis-related diseases with high unmet needs. Based on the unique and critical role of the soluble protein CCL 24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block the activity of CCL 24. CM-101 has the potential to treat a variety of serious and life-threatening inflammatory and fibrotic diseases and is currently in clinical development for orphan diseases, primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
